NAFCILLIN SODIUM

N/A

Manufactured by Athenex Pharmaceutical Division, LLC.

1,697 FDA adverse event reports analyzed

Last updated: 2026-04-15

About NAFCILLIN SODIUM

NAFCILLIN SODIUM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Athenex Pharmaceutical Division, LLC.. The most commonly reported adverse reactions for NAFCILLIN SODIUM include RENAL FAILURE ACUTE, RASH, DRUG INEFFECTIVE, ACUTE KIDNEY INJURY, PYREXIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for NAFCILLIN SODIUM.

Top Adverse Reactions

RENAL FAILURE ACUTE64 reports
RASH56 reports
DRUG INEFFECTIVE55 reports
ACUTE KIDNEY INJURY49 reports
PYREXIA44 reports
TUBULOINTERSTITIAL NEPHRITIS43 reports
HYPOKALAEMIA39 reports
RENAL FAILURE39 reports
BLOOD CREATININE INCREASED36 reports
DRUG INTERACTION35 reports
DIARRHOEA29 reports
NAUSEA28 reports
VOMITING28 reports
ANXIETY27 reports
DRUG HYPERSENSITIVITY27 reports
PAIN27 reports
PRURITUS25 reports
RENAL IMPAIRMENT25 reports
SEPSIS25 reports
NEUTROPENIA24 reports
DYSPNOEA21 reports
INJURY21 reports
STAPHYLOCOCCAL BACTERAEMIA21 reports
UNEVALUABLE EVENT21 reports
NEPHROPATHY TOXIC20 reports
DEATH19 reports
OFF LABEL USE18 reports
RENAL INJURY18 reports
ASTHENIA17 reports
NEPHRITIS INTERSTITIAL17 reports
STAPHYLOCOCCAL INFECTION17 reports
ANAEMIA16 reports
ANHEDONIA16 reports
BLOOD BILIRUBIN INCREASED16 reports
DRUG INDUCED LIVER INJURY16 reports
EMOTIONAL DISTRESS16 reports
FEAR16 reports
HYPOTENSION16 reports
RESPIRATORY FAILURE16 reports
VASCULAR DEVICE INFECTION16 reports
HEPATOTOXICITY15 reports
RASH GENERALISED15 reports
SEPTIC SHOCK15 reports
CONDITION AGGRAVATED14 reports
MEDICATION ERROR14 reports
PNEUMONIA14 reports
THROMBOCYTOPENIA14 reports
ABDOMINAL PAIN13 reports
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS13 reports
EOSINOPHILIA13 reports
DEPRESSION12 reports
INTERNATIONAL NORMALISED RATIO INCREASED12 reports
MENTAL STATUS CHANGES12 reports
TREATMENT FAILURE12 reports
URTICARIA12 reports
BLOOD UREA INCREASED11 reports
BRADYCARDIA11 reports
CHEST PAIN11 reports
COUGH11 reports
FATIGUE11 reports
HYPERSENSITIVITY11 reports
HYPERTENSION11 reports
RASH ERYTHEMATOUS11 reports
RENAL TUBULAR NECROSIS11 reports
STRESS11 reports
URINARY TRACT INFECTION11 reports
WEIGHT DECREASED11 reports
BACK PAIN10 reports
CARDIAC ARREST10 reports
HAEMATURIA10 reports
HAEMOGLOBIN DECREASED10 reports
HYPOXIA10 reports
JAUNDICE10 reports
PLATELET COUNT DECREASED10 reports
SEROTONIN SYNDROME10 reports
WHITE BLOOD CELL COUNT DECREASED10 reports
ANAPHYLACTIC REACTION9 reports
ARTHRALGIA9 reports
CARDIOGENIC SHOCK9 reports
ENDOCARDITIS9 reports
ERYTHEMA9 reports
HAEMOPTYSIS9 reports
NEPHRITIS9 reports
SHOCK9 reports
ACUTE RESPIRATORY FAILURE8 reports
ALANINE AMINOTRANSFERASE INCREASED8 reports
ASPARTATE AMINOTRANSFERASE INCREASED8 reports
CLOSTRIDIUM DIFFICILE COLITIS8 reports
CONFUSIONAL STATE8 reports
DEHYDRATION8 reports
DEVICE RELATED INFECTION8 reports
FOETAL EXPOSURE DURING PREGNANCY8 reports
HEADACHE8 reports
HYPERBILIRUBINAEMIA8 reports
LEUKOPENIA8 reports
OEDEMA PERIPHERAL8 reports
ABDOMINAL DISTENSION7 reports
AGITATION7 reports
ATRIAL FIBRILLATION7 reports
CELLULITIS7 reports

Report Outcomes

Out of 900 classified reports for NAFCILLIN SODIUM:

Serious 84.4%Non-Serious 15.6%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male502 (64.2%)
Female259 (33.1%)
Unknown21 (2.7%)

Reports by Age

Age 5824 reports
Age 6924 reports
Age 7124 reports
Age 6623 reports
Age 5321 reports
Age 5920 reports
Age 6019 reports
Age 7019 reports
Age 6218 reports
Age 4815 reports
Age 6715 reports
Age 814 reports
Age 5214 reports
Age 6814 reports
Age 5413 reports
Age 6112 reports
Age 7412 reports
Age 8312 reports
Age 4611 reports
Age 5511 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with NAFCILLIN SODIUM?

This profile reflects 1,697 FDA FAERS reports that mention NAFCILLIN SODIUM. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for NAFCILLIN SODIUM?

Frequently reported terms in FAERS include RENAL FAILURE ACUTE, RASH, DRUG INEFFECTIVE, ACUTE KIDNEY INJURY, PYREXIA, TUBULOINTERSTITIAL NEPHRITIS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures NAFCILLIN SODIUM?

Labeling and FAERS entries often list Athenex Pharmaceutical Division, LLC. in connection with NAFCILLIN SODIUM. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.